J P Morgan Chase & Co set a $82.00 price target on Gilead Sciences, Inc. (NASDAQ:GILD) in a research note issued to investors on Tuesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the stock. Citigroup Inc. boosted their target price on shares of Gilead Sciences to $87.00 in a research report on Thursday, January 26th. RBC Capital Markets cut their target price on shares of Gilead Sciences to $75.00 in a research report on Wednesday, February 8th. Jefferies Group LLC boosted their target price on shares of Gilead Sciences from $93.00 to $95.00 and gave the company a buy rating in a research report on Tuesday, October 25th. Cowen and Company set a $120.00 target price on shares of Gilead Sciences and gave the company a buy rating in a research report on Sunday, October 23rd. Finally, Piper Jaffray Companies set a $108.00 target price on shares of Gilead Sciences and gave the company a buy rating in a research report on Thursday, October 20th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $87.20.

Gilead Sciences (NASDAQ:GILD) opened at 70.31 on Tuesday. The company has a market cap of $92.11 billion, a price-to-earnings ratio of 7.07 and a beta of 1.11. Gilead Sciences has a 12-month low of $65.38 and a 12-month high of $103.10. The company’s 50 day moving average is $71.76 and its 200 day moving average is $75.36.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.61 by $0.09. The company earned $7.30 billion during the quarter, compared to analyst estimates of $7.16 billion. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. The firm’s quarterly revenue was down 13.9% compared to the same quarter last year. During the same period in the previous year, the business posted $3.32 earnings per share. Analysts forecast that Gilead Sciences will post $8.57 earnings per share for the current fiscal year.

“J P Morgan Chase & Co Reiterates $82.00 Price Target for Gilead Sciences, Inc. (GILD)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of international trademark & copyright law. The legal version of this story can be read at http://www.watchlistnews.com/j-p-morgan-chase-co-reiterates-82-00-price-target-for-gilead-sciences-inc-gild/1121772.html.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Stockholders of record on Thursday, March 16th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, March 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.96%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.47. Gilead Sciences’s dividend payout ratio is currently 18.91%.

In other news, insider John C. Martin sold 73,337 shares of the stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the sale, the insider now owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.40% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Greatmark Investment Partners Inc. purchased a new stake in shares of Gilead Sciences during the second quarter valued at $2,835,000. Sequoia Financial Advisors LLC increased its stake in shares of Gilead Sciences by 10.0% in the second quarter. Sequoia Financial Advisors LLC now owns 43,898 shares of the biopharmaceutical company’s stock valued at $3,662,000 after buying an additional 3,996 shares in the last quarter. CAM Group Holding A S increased its stake in shares of Gilead Sciences by 1.1% in the second quarter. CAM Group Holding A S now owns 3,580,736 shares of the biopharmaceutical company’s stock valued at $298,705,000 after buying an additional 38,964 shares in the last quarter. Penobscot Investment Management Company Inc. increased its stake in shares of Gilead Sciences by 7.8% in the second quarter. Penobscot Investment Management Company Inc. now owns 6,491 shares of the biopharmaceutical company’s stock valued at $541,000 after buying an additional 470 shares in the last quarter. Finally, Stevens First Principles Investment Advisors increased its stake in shares of Gilead Sciences by 5.7% in the second quarter. Stevens First Principles Investment Advisors now owns 13,360 shares of the biopharmaceutical company’s stock valued at $1,114,000 after buying an additional 725 shares in the last quarter. 74.19% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.